Security Snapshot

Compass Therapeutics, Inc. - COMMON STOCK (CMPX) Institutional Ownership

CUSIP: 20454B104

13F Institutional Holders and Ownership History from Q4 2021 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

79

Shares (Excl. Options)

42.55MFull value: 42,554,449 · shares · 30 Sep 2026

Price

$1.04

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / COMMON STOCK
Symbol
CMPX on Nasdaq
All holders as of 30 Sep 2026
Q3 2026
Total 13F shares
42,554,449
Latest holder snapshot 5 signals
Total 13F value
$44,259,679
Portfolio coverage rank
0%
Share change
-6,555,590
Value change
-$9,959,126
Number of holders
79
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
179,952,047
SEC-reported price per share
$0.86
Insider filing price
$0.86
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • CMPX - Compass Therapeutics, Inc. - COMMON STOCK is tracked under CUSIP 20454B104.
  • 79 institutions reported positions in Q3 2026.
  • 11 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 214 to 79 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $362.51MFull value: $362,506,628 · USD · 30 Jun 2026
    to
    $44.26MFull value: $44,259,679 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 79 institutions filings for Q3 2026.

Open SEC evidence

Security key

20454B104

13F reference period

Q3 2026

13F holders

79

13D/G owners

11

CIK / CUSIP context first

Open Q3 2026 holders CMPX full holder history Compass Therapeutics, Inc. SEC filings Compass Therapeutics, Inc. company facts Compass Therapeutics, Inc. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
11
Security
CMPX
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
TANG CAPITAL MANAGEMENT LLC 10% +1.9% $60,117,785 +$12,881,057 17,176,510 +27% TANG CAPITAL MANAGEMENT, LLC 30 Sep 2025
ORBIMED ADVISORS LLC 8.9% -19% $41,093,984 15,219,994 0% ORBIMED ADVISORS LLC 13 Aug 2025
SUVRETTA CAPITAL MANAGEMENT, LLC 8.2% +60% $44,559,662 +$21,967,265 14,101,159 +97% Suvretta Capital Management, LLC 13 Aug 2025
BlackRock, Inc. 5.2% +12% $49,788,728 +$15,426,163 9,271,644 +45% BlackRock, Inc. 31 Dec 2025
Commander Aggregator, LP 4.5% $24,610,554 7,788,150 Commander Aggregator, LP 14 Aug 2025
BIOTECHNOLOGY VALUE FUND L P 4.3% -16% $41,076,014 -$5,211,486 7,764,842 -11% BVF PARTNERS L P/IL 31 Mar 2026
STATE STREET CORP 4.3% -24% $6,654,627 -$1,905,515 7,737,938 -22% STATE STREET CORPORATION 30 Sep 2026
Vivo Opportunity Fund Holdings, L.P. 4% -22% $15,784,585 -$3,916,609 7,207,573 -20% Vivo Opportunity Fund Holdings, L.P. 30 Jun 2026
Blackstone Holdings II L.P. 3.4% $31,917,408 6,126,182 Blackstone Alternative Asset Management Associates LLC 31 Dec 2025
ADAGE CAPITAL PARTNERS GP, L.L.C. 4.4% $11,629,931 5,994,810 Adage Capital Management, L.P. 31 Dec 2024
MPM BioImpact LLC 4.1% -35% $15,180,764 -$7,952,556 5,622,505 -34% MPM BioImpact LLC 30 Jun 2025
As of 30 Sep 2026, 79 institutional investors reported holding
42.55MFull value: 42,554,449 · shares · 30 Sep 2026
shares of Compass Therapeutics, Inc. - COMMON STOCK (CMPX). This represents 24% of the company’s total
179.95MFull value: 179,952,047 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
23%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
STATE STREET CORP 4.3% 7,737,938 -22% 0% $8,047,456
VANGUARD CAPITAL MANAGEMENT LLC 3.3% 5,994,782 -2% 0% $6,234,573
Qube Research & Technologies Ltd 2.3% 4,170,894 +13% 0% $4,337,730
GEODE CAPITAL MANAGEMENT, LLC 2% 3,644,115 -4.5% 0% $3,790,929
Vivo Capital, LLC 1.9% 3,423,547 -56% 0.39% $3,560,489
VANGUARD PORTFOLIO MANAGEMENT LLC 1.2% 2,077,875 -45% 0% $2,160,990
Fisher Asset Management, LLC 1.1% 1,945,821 +40% 0% $2,023,653
MARSHALL WACE, LLP 0.95% 1,707,238 +410% 0% $1,775,529
Birchview Capital, LP 0.88% 1,575,000 -6% 0.95% $1,638,000
MORGAN STANLEY 0.83% 1,494,654 +103% 0% $1,554,441
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 0.67% 1,208,004 0% $1,256,324
VANGUARD FIDUCIARY TRUST CO 0.54% 973,188 -2.8% 0% $1,012,116
ROYCE & ASSOCIATES LP 0.49% 888,393 -34% 0.01% $923,929
DIMENSIONAL FUND ADVISORS LP 0.48% 855,724 +58% 0% $890,770
CM Management, LLC 0.42% 750,000 +36% 0.52% $780,000
Connor, Clark & Lunn Investment Management Ltd. 0.38% 677,252 +29% 0% $704,342
Quadrature Capital Ltd 0.35% 638,820 +490% 0% $664,373
NATIXIS 0.17% 310,800 +4.4% 0% $323,232
ALPS ADVISORS INC 0.13% 236,892 +30% 0% $246,368
Rafferty Asset Management, LLC 0.12% 208,702 +9.8% 0% $217,050
PANAGORA ASSET MANAGEMENT INC 0.11% 202,635 -8.8% 0% $210,740
Creative Planning 0.09% 161,774 -12% 0% $168,245
Virtus Investment Advisers, LLC 0.09% 156,322 -3% 0.04% $162,575
DEUTSCHE BANK AG\ 0.06% 114,236 -15% 0% $118,805
GROUP ONE TRADING LLC 0.06% 107,068 +31% 0% $111,351

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
20
Headline period
Q3 2026
Rows shown
1-20 of 20
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 42,554,449 $44,259,679 -$9,959,126 $1.04 79
2026 Q2 165,537,068 $362,506,628 -$119,586,467 $2.19 214
2026 Q1 173,194,999 $916,047,041 +$49,017,701 $5.29 199
2025 Q4 164,168,134 $881,588,986 +$65,007,494 $5.37 174
2025 Q3 151,052,849 $528,694,287 +$149,920,554 $3.50 124
2025 Q2 108,253,035 $281,458,749 +$738,261 $2.60 103
2025 Q1 108,444,414 $206,047,938 +$13,824,994 $1.90 107
2024 Q4 101,374,021 $146,996,022 +$1,180,763 $1.45 92
2024 Q3 92,186,861 $169,597,729 +$881,089 $1.84 79
2024 Q2 92,861,661 $93,412,908 -$5,271,746 $1.00 81
2024 Q1 94,552,324 $187,180,490 +$18,089,983 $1.98 77
2023 Q4 86,111,898 $134,344,397 -$2,317,455 $1.56 76
2023 Q3 89,720,729 $176,712,745 -$1,697,948 $1.97 76
2023 Q2 90,478,972 $287,651,504 +$28,216,829 $3.18 72
2023 Q1 81,516,748 $266,518,963 +$1,871,389 $3.27 72
2022 Q4 79,833,267 $401,391,571 +$78,919,542 $5.03 54
2022 Q3 63,858,418 $145,631,000 +$3,917,942 $2.28 36
2022 Q2 61,892,616 $163,922,000 +$665,806 $2.65 31
2022 Q1 62,376,106 $85,353,000 -$4,074,753 $1.37 33
2021 Q4 63,567,962 $201,611,000 +$198,091,000 $3.17 37
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .